Supply of products by Aurobindo Pharma Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and use of therapeutic goods in Australia, including medicines, medical devices, and blood products, ensuring their quality, safety, and efficacy. This Act aims to protect public health by controlling the importation, supply, and advertising of therapeutic goods. The Act was introduced by the Commonwealth Parliament to address the need for a comprehensive framework governing the therapeutic goods market. In this context, the Therapeutic Goods Act 1989 serves to regulate the therapeutic goods industry and to protect consumers by ensuring that therapeutic goods are of acceptable quality and safe for use. On March 8, 2013, the delegate of the Secretary of the Department of Health and Ageing, acting under subsections 14 and 14A of the Therapeutic Goods Act 1989, provided consent for the supply of specific ondansetron orally disintegrating tablets by Aurobindo Pharma Australia Pty Ltd, despite the products not meeting the disintegration requirements of the United States Pharmacopeia Monograph. This consent is conditional on the products conforming to the disintegration test described in the company's application for product registration, with a disintegration requirement of not more than 60 seconds. This decision exemplifies the Act's role in balancing regulatory requirements with the need to facilitate access to therapeutic goods that meet acceptable safety and quality standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing products such as medicines, medical devices, and blood products. Under this Act, the delegate of the Secretary of the Department of Health and Ageing can provide consent for the supply of specific products that do not fully conform to certain standards, as long as they meet alternative conditions. In this particular instance, the Act applies to the products supplied by Aurobindo Pharma Australia Pty Ltd, which includes various ondansetron orally disintegrating tablets. This consent is limited to the Commonwealth of Australia and applies to the entities involved in the manufacture and supply of these therapeutic goods. The Act does not specify exclusions or exemptions in this notice, but it does impose conditions under which the consent is valid, such as the requirement that the products meet a disintegration test of not more than 60 seconds. The scope of application of the Act can be extended or further defined through subordinate instruments, which may include regulations or guidelines issued under the authority of the Act.

Key Provisions

Section 14 and 14A of the Therapeutic Goods Act 1989 allows for the supply of therapeutic goods that do not conform to the standards set by the United States Pharmacopeia Monograph, provided certain conditions are met. In this case, the delegate of the Secretary of the Department of Health and Ageing has given consent for Aurobindo Pharma Australia Pty Ltd to supply ondansetron orally disintegrating tablets, which do not meet the disintegration requirements of not more than 10 seconds as outlined in the Monograph. However, the consent is subject to the condition that the products conform to the disintegration test described in the registration application, with a requirement of not more than 60 seconds. The Therapeutic Goods Act 1989 imposes several obligations and requirements on parties and entities it governs. Firstly, the delegate of the Secretary must ensure that therapeutic goods supplied in Australia meet certain standards of quality, safety and efficacy. This includes ensuring that products conform to the standards set by the United States Pharmacopeia Monograph, unless consent is given under Section 14 or 14A. Secondly, companies seeking to supply therapeutic goods must apply for registration with the Therapeutic Goods Administration (TGA) and provide all necessary information and evidence to demonstrate that their products meet the required standards. Finally, the TGA has the power to inspect and test products to ensure compliance with the Act. The Therapeutic Goods Act 1989 also provides for offences, penalties and consequences for breach of its provisions. For example, Section 33DA provides that a person who supplies a therapeutic good that is not registered, or that does not comply with the conditions of registration, is guilty of an offence and may be subject to a fine of up to $222,200 for a corporation or $44,440 for an individual. Similarly, Section 33DB provides that a person who makes a false or misleading representation in relation to a therapeutic good is guilty of an offence and may be subject to a fine of up to $1,111,000 for a corporation or $222,200 for an individual. These penalties reflect the importance of ensuring that therapeutic goods supplied in Australia are safe, effective and of high quality.